PRIME status for Ignyta’s entrectinib

18th October 2017 Uncategorised 0

European regulators have awarded Ignyta’s cancer drug entrectinib Priority Medicines (PRIME) designation, potentially placing the treatment on a faster path to approval.

More: PRIME status for Ignyta’s entrectinib
Source: News